Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from BTIG Research

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating reaffirmed by analysts at BTIG Research in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $192.00 price target on the stock. BTIG Research’s price target would suggest a potential upside of 88.24% from the company’s previous close.

A number of other analysts have also recently issued reports on PVLA. Truist Financial boosted their target price on Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a report on Monday, December 15th. TD Cowen lifted their target price on Palvella Therapeutics from $97.00 to $133.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Canaccord Genuity Group increased their price objective on Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Cantor Fitzgerald upped their price objective on Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Finally, Oppenheimer reissued an “outperform” rating and issued a $200.00 price target on shares of Palvella Therapeutics in a research note on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $158.69.

Palvella Therapeutics Price Performance

Palvella Therapeutics stock traded down $1.98 during trading on Friday, reaching $102.00. 74,446 shares of the company were exchanged, compared to its average volume of 197,158. The stock’s 50 day simple moving average is $95.63 and its two-hundred day simple moving average is $67.42. The company has a market capitalization of $1.21 billion, a P/E ratio of -38.78 and a beta of -0.16. Palvella Therapeutics has a 52-week low of $12.10 and a 52-week high of $114.69.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18). As a group, equities analysts forecast that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Insider Activity

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total value of $415,013.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 20.50% of the stock is owned by company insiders.

Institutional Trading of Palvella Therapeutics

Institutional investors have recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in Palvella Therapeutics during the first quarter valued at about $7,553,000. Goldman Sachs Group Inc. purchased a new position in shares of Palvella Therapeutics during the first quarter valued at about $533,000. Clio Asset Management LLC bought a new position in shares of Palvella Therapeutics in the 2nd quarter worth approximately $2,063,000. Geode Capital Management LLC lifted its position in Palvella Therapeutics by 84.7% during the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock valued at $3,923,000 after buying an additional 79,787 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in Palvella Therapeutics during the second quarter worth about $37,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.